x

Posted 05 December, 2023

CONTRAFECT Corp appointed new CEO

CEO Change detected for ticker OTC:CFRX in a 8-K filed on 05 December, 2023.


  On December 4, 2023, Michael Messinger, Chief Executive Officer, President and Chief Financial Officer, and Natalie Bogdanos, General Counsel, Corporate Secretary & Data Protection Officer, tendered their resignations, effective on such date.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of CONTRAFECT Corp
Health Care/Life Sciences • Biotechnology
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Market Cap
$258K
View Company Details
CONTRAFECT Corp by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 4, 2023, Michael Messinger, Chief Executive Officer, President and Chief Financial Officer, and Natalie Bogdanos, General Counsel, Corporate Secretary & Data Protection Officer, tendered their resignations, effective on such date. As of December 4, 2023, the Company has no officers, consultants or employees.

On December 4, 2023, directors Lishan Aklog, Sol J. Barer, Jane F. Barlow, Steven C. Gilman, David N. Low, Jr., Michael J. Otto, Roger J. Pomerantz and Cary W. Sucoff resigned as members of the Company's Board of Directors. The Company has no current members of the Board of Directors.